Pharsight Corp

Pharsight — Investor Presentation (November 2004)

38 slides from Pharsight's investor presentation, Nov 22, 2004

  1. Slide 1: Pharsight Investor Presentation, November 2004

    Slide 1: Pharsight Investor Presentation, November 2004

    Exhibit 99.1 Pharsight November Shawn Cynthia Copyright O’Connor Stephens Corporation ©2004 2004President SVP Pharsight. Investor & CFO &All CEO Presentation rights reserved.

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking This customer profitability, Forward-looking installations stock conditions focus may disclosed expectations on Copyright CONFIDENTIAL information be presentation dividends orunable operating demand, under © mayand and reflected 2004 to available affect the may related revenue statem

  3. Slide 3: Pharsight is delivering breakthrough improvement in clinical drug development

    Slide 3: Pharsight is delivering breakthrough improvement in clinical drug development

    Pharsight®© Delivering Copyright efficiencies CONFIDENTIALbreakthrough is… 2004 Pharsight. improvement All rights in reserved. the clinical drug development process to pharmaceutical companies, by accelerating client product time-to-market and improving client development

  4. Slide 4: Drug Research and Development Productivity Challenge

    Slide 4: Drug Research and Development Productivity Challenge

    Our Drug Research High Clinical Long, drugs Significant Productivity 1 2 Copyright CONFIDENTIAL 2002 PhRMA Market throughput Development produce risky Estimated Development $25 2003 ©Productivity and Opportunity: Continues 2004 Billion1 revenues Industry complex screening Global Pharsight. Cost $48

  5. Slide 5: Pharsight Profile

    Slide 5: Pharsight Profile

    Founded Background Profile Headquarters East Headcount US, OTCBB: Business Unique Market Opportunity Copyright CONFIDENTIAL Europe, Coast leading provider 1995; and PHST © Office - Australia to approx 2004 Products - Mountain leverage IPO provider of-Pharsight. Cary, strategic August 80and and of NC

  6. Slide 6: Executive Team

    Slide 6: Executive Team

    Executive Shawn Cynthia Mark Greg President SVP IVAX, GloboMax, VP Managing Copyright CONFIDENTIAL &Business Research Global Consulting & Software Drug Lee, Robillard Lead Merrell O’Connor Chief Stephens & Team PhD Director, © Development Sales Scientist, FDA Chief 2004 &Financial Development Produc

  7. Slide 7: Software Products

    Slide 7: Software Products

    Software Products Copyright © 2004 Pharsight. All rights reserved.

  8. Slide 8: WinNonlin

    Slide 8: WinNonlin

    WinNonLin® Industry Key Used Increases Potential Maintain Provide Sales Annual ASP Copyright CONFIDENTIAL Software Benefits $3,000 to Model subscription simulate upgrade Standard Growth market productivity ©-2004 $6,500 Offerings (“WNL™”) path share effects Drivers for Pharsight. fee per to Pharmaco

  9. Slide 9: Trial Simulator

    Slide 9: Trial Simulator

    TrialBenefits Software-Based Key Minimize Formalize Quantify Growth Increase Sales Annual Copyright CONFIDENTIAL Software Simulator™ Model subscription Drivers interoperability uncertainty risk assumptions © 2004 Offerings ofClinical trial (“TS2™”) Pharsight. fee &design Lower with TrialAll other De

  10. Slide 10: Pharsight Knowledgebase Server

    Slide 10: Pharsight Knowledgebase Server

    Pharsight Enterprise Key Dramatically Increases Supports Potential Leverage Optimize Expand Sales Subscription Deployment Post-contract Average Copyright CONFIDENTIAL Software Benefits Model utility contract Growth compliance installed productivity adoption Knowledge © Data services, and 2004 improv

  11. Slide 11: Drug Model Explorer

    Slide 11: Drug Model Explorer

    Key Software Drug Software-Based Introduced Facilitates Enables Potential Expand Sales Annual Copyright CONFIDENTIAL Model subscription client utility more Growth © more inExplorer™ 2004 fiscal flexible Offerings base and Communication efficient Drivers Pharsight. footprint of 2004 fee early scenari

  12. Slide 12: Software Market Acceptance

    Slide 12: Software Market Acceptance

    Software Over All early DMXTM Importance 4 7 14 Copyright ofPKSTM top the adopters 90020 top Products customers product © Pharma of 10 20 customers 2004 DMXTM of Pharma our Pharsight. Market apply (FY2004) new to-date are mentioned our Acceptance PKSTM computer-assisted All rights by customers 1rese

  13. Slide 13: Drug Development Consulting Services

    Slide 13: Drug Development Consulting Services

    Drug Development Copyright © 2004 Pharsight. ConsultingAllServices rights reserved.

  14. Slide 14: Consulting Methodology

    Slide 14: Consulting Methodology

    Drug A Decrease Increase Improve Copyright formal, Development drug # clinical late time-to-market quantitative, ©of 2004 drugs stage development quality Pharsight. reaching attrition Consulting model-based andproductivity commercial market/$ AllMethodology rights decision-making invested reserved.

  15. Slide 15: Drug-Disease Models

    Slide 15: Drug-Disease Models

    Models: The Drug-Disease Trial Predictive Dynamic Pharmacological Literature PK/PD Copyright Annual CONFIDENTIAL 900 10th-90th 2000800 foundation Models 2002 Simulation Cash 700 The Financial %ile Clinical Market © 2004 600 Foundation 2004 Flow Models range of2006 models 500 Models the Pharsight. Da

  16. Slide 16: Technology and Services Across Drug Development Phases

    Slide 16: Technology and Services Across Drug Development Phases

    DrugPhase LEVEL POTENTIAL Candidate Preclinical Early Proof-of-concept (I/IIa) Late Go/no-go (IIb/III) Life-cycle Post-Approval Phase Label Scaling Product Support Novel (integrated Copyright Development Phase expansion IIIb/IV Technology: (competitors, profile OF in-licensing decision prioritizatio

  17. Slide 17: Aventis Testimonial

    Slide 17: Aventis Testimonial

    FORBES Aventis simulation, estimates Frank Executive Copyright Douglas turned that ASAP VP ©“We 2004 the ofto Aventis stopped |Drug aPharsight October Pharsight. computer Innovation Chief funding 7,computer 2002 All model Scientific rights development and from model Approval reserved. Officer a smal

  18. Slide 18: Consulting Services Potential Growth Drivers

    Slide 18: Consulting Services Potential Growth Drivers

    Drug Development Increased Migration Expanding Ability Copyright to acceptance recruit from ©scope 2004 one-off and and Pharsight. Consulting retain of increasing projects modeling skilled AllServices to efficiency rights and systematic scientific simulation reserved. Potential ofstaff consulting ap

  19. Slide 19: Consulting Services Market Acceptance

    Slide 19: Consulting Services Market Acceptance

    Drug 25 9 Average Copyright ofofthe Development toptop duration 50 ©10 Pharma 2004 Pharma ofPharsight. Consulting client have haveutilized relationships utilized AllServices: rights ourour strategic reserved. –services Market 4 years 3 consulting Acceptance CONFIDENTIAL services All 5 of the top 5 P

  20. Slide 20: Financial Overview

    Slide 20: Financial Overview

    Financial Overview Copyright © 2004 Pharsight. All rights reserved.

  21. Slide 21: FY04 Accomplishments and FY05 Objectives

    Slide 21: FY04 Accomplishments and FY05 Objectives

    FY04year Positive Effected Y-Y Achieved Introduced Fiscal Continued 27%-30% Full Profitability Excluding Expansion Additional Copyright revenue reductions Accomplishments Year revenue operating net profitability positive Y/Y © impact revenue of new 2004 2005 growth income 2004 DMX in product momentu

  22. Slide 22: First Half FY05 Progress

    Slide 22: First Half FY05 Progress

    FirstFY05 Progress Continued Q2 1H Profitability Expansion Continuing Return Addition Copyright Half ofagainst of 26% 31% profitability Daniel (1H) © revenue of by focus Robert 2004 DMX Top Y/Y FY05 FY05 Weiner, on 5Pharsight. growth Leary, Growth capabilities Pharma new Accomplishments Objectives P

  23. Slide 23: Summary Statement of Operations

    Slide 23: Summary Statement of Operations

    Summary (‘000s Q2 1H Revenues Income Net EPS WASO—basic WASO—diluted Copyright CONFIDENTIAL FY05 FY04 income (common), except (loss) $Statement ©(loss) 5,072 2004 per from 19,087 basic 20,674 share 421 attributable $Pharsight. operations 4,017 of& (595) 19,050 Operations data) 19,050 diluted $ 10,10

  24. Slide 24: Segment Results Summary

    Slide 24: Segment Results Summary

    Summary (‘000s) Q2 1H SOFTWARE 79% STRATEGIC Revenues Income Copyright FY05 FY04 4,310 (loss) $2,564 Operating ©84% 2004 PRODUCTS CONSULTING from 3,017 100% Pharsight. operations Results 76% $1,837 $ by % All SERVICES 251 236 100% Segment $rights %9% 10% $ $4,950 %(311) reserved. (129) $– % Y/Y -17%

  25. Slide 25: Summary Balance Sheet

    Slide 25: Summary Balance Sheet

    Summary March June Sept Cash ASSETS (‘000s) LIABILITIES A/P Deferred Redeemable Copyright &30, &Accrued 31, Cash 2004 Revenue—Long Balance © 2004 Conv 2004 Equivalents &Expenses STOCKHOLDERS’ Pharsight. Sheet Pref Stock September $Term 1,957 10,027 All 6,164 516 rights $ $2,518 6,266 30, 180 8,463 D

  26. Slide 26: Equity Structure

    Slide 26: Equity Structure

    Equity (All Series Common 1,814,662 Preferred Warrants Dividend Automatically Conversion: Upon At Redemption: Copyright election share close AStructure 1,814,662 exercisable conversion rights: Shares Equivalent data Units ©of of2004 at public upon asSeries least 8%/annum O/S: ofPharsight. / consent

  27. Slide 27: Quarterly Revenues

    Slide 27: Quarterly Revenues

    Quarterly Software (‘000s) Q1 Copyright FY04 Products Q2 Revenues © 2004 FY04Pharsight. Strategic Q3 FY04Consulting All Q4 rights FY04 reserved. Q1 $6,000 FY05$5,000 CONFIDENTIAL Q2 FY05 $4,000 $3,000 $2,000 $1,000 $0

  28. Slide 28: Half Year Revenue Trend

    Slide 28: Half Year Revenue Trend

    FirstFY03 Software (‘000s) 1H Copyright HalfProducts 1H Annual © 2004 FY04 Revenue Pharsight. Strategic 1H FY05 Trend Consulting All rights reserved. $12,000 $10,000 CONFIDENTIAL $8,000 $6,000 $4,000 $2,000 $0

  29. Slide 29: Quarterly Gross Profit by Segment

    Slide 29: Quarterly Gross Profit by Segment

    Quarterly (Percentage Strategic 90% Q1 Copyright FY04 80%Consulting Q2 Gross 70% ©of2004 FY04 Segment 60% Profit Pharsight. Q3 50% Software FY04 Revenues) 40%All Q4 Products 30% rights FY04 20% reserved. Q110% FY05 0%CONFIDENTIAL Q2 FY05

  30. Slide 30: Sequential Profitability

    Slide 30: Sequential Profitability

    Sequential (‘000s) Q1 Profitability Revenues Copyright FY04$5,500 Q2 Costs © Profitability achieved 2004 FY04 $5,300 & Pharsight. Expenses Q3Q4 $5,100 FY04 FY04 All Q4 $4,900 rights FY04 $4,700 reserved. Q1 FY05 $4,500 CONFIDENTIAL Q2$4,300 FY05 $4,100 $3,900 $3,700 $3,500

  31. Slide 31: Current Summary

    Slide 31: Current Summary

    Current Summary And All Sustainable Copyright Support Continued Pharma ©Growth Our 2004 Positive Market Drive Pharsight. andTowards Trends… Profitability Momentum All rights Continuing Demonstrated in reserved. FY05 Pharsight WeCONFIDENTIAL Reiterate in 1HInvestment FY05… Our FY05 in Revenue Guidanc

  32. Slide 32: Appendix: Drug Development Consulting Services Case Studies

    Slide 32: Appendix: Drug Development Consulting Services Case Studies

    Drug Development Appendix: Copyright © 2004 Pharsight. ConsultingAllServices—Case rights reserved.Studies

  33. Slide 33: Case Study: Trial Design Optimization

    Slide 33: Case Study: Trial Design Optimization

    Drug was Case Critical Exploration Approach Predictive Optimized Results Estimated Impact Trial Copyright Study: Development Business success & savings modeling ©trial study of Trial Technologies 2004 new design design Issue Design as of Pharsight. Consulting indication predicted; of 25% using key (

  34. Slide 34: Case Study: Phase II Go/No-Go Decision

    Slide 34: Case Study: Phase II Go/No-Go Decision

    Drug conducted Case Critical Optimal Approach Drug-disease Alternate Trial Results Early Impact Novel Copyright Study: Development attrition: design failed Business Phase trial & ©Trial Technologies 2004 models yielded to designs $1.4-$3.8 IIbased meet proof-of-concept Issue Design Pharsight. Consul

  35. Slide 35: Case Study: Program Strategy and Decision Making

    Slide 35: Case Study: Program Strategy and Decision Making

    Drugnew Case Critical For Approach Modeled Model DMX Results Supported Impact Copyright Study: Development used insights Business compound dose-response & © critical inUse Technologies 2004 ‘real-time’ made of Issue question Pharsight. Consulting Drug inavailable core for decision-making Model Utili

  36. Slide 36: Case Study: Product Positioning

    Slide 36: Case Study: Product Positioning

    Drug Study: Case Critical Product Approach Predictive Failure Results Further Impact Copyright Development to development Business positioning demonstrate & treatment ©Go/No-Go Technologies 2004Issue Pharsight. Consulting vs. response-models was equivalent first-generation Decision halted, Utilized

  37. Slide 37: Proprietary Notices

    Slide 37: Proprietary Notices

    Proprietary Notices No Pharsight DMXTM, All Copyright part contents otherofbrand Corporation. © Trial this Notice Copyright 2004 document and SimulatorTM Pharsight. product WinNonLin® ©2004 maynames All and be Pharsight rights reproduced TSTM areand trademarks reserved. Corporation. are Pharsight® o

  38. Slide 38: Pharsight

    Slide 38: Pharsight

    Pharsight

Source: SEC EDGAR · 8-K filed Nov 22, 2004

More decks from Pharsight Corp